← Back to signals
JAZZ
AVOIDJazz Pharmaceuticals plc
Health Care
10.00
PEGY ratio
Rank #453
Why This Matters
This stock appears overvalued relative to its growth and dividend yield. Strong projected growth of 10000.0% annually over 5 years.
JAZZ trades at 1970.8x earnings against 25.0% capped growth (actual 21343.8%) (no dividend) (PEGY 10.00). The valuation appears stretched relative to the available growth and income.
~ Growth estimate uses historical CAGR (forward estimates unavailable)
- • Growth rate derived from historical CAGR — limited analyst coverage.
- • Growth rate capped at 25% for PEGY calculation (actual: 21343.8%). Per Peter Lynch methodology, growth above 25% is rarely sustainable over 5 years.
Scan date: 2026-05-29
Valuation
1970.8x
P/E Ratio
Growth
10000.0%
5yr EPS
Income
0.0%
Div Yield
PEGY Components
PEGY Score10.00
Denominator25.0%
EPS (TTM)$0.12
Market Data
Price$236.49
ExchangeNASDAQ
S&P 500
What Changed
PEGY Score
10.00→10.00(+0.00)
Rank
#451→#453(2 positions)
vs 7 days ago
Portfolio Context
Founder does not hold this stock.
Not in your portfolio.
Sector: Health Care
PEGY History — 90 days
Data: Yahoo Finance • Updated nightly 11 PM ET • For informational purposes only